.
.eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
the report was compiled by outside researchers who went into the fda�s own database of �serious adverse [medical-drug] events.� .
$17
OFF DEAL
OFF DEAL
GET DEAL
218 Used Today
50%
OFF DEAL
OFF DEAL
$20
OFF DEAL
OFF DEAL
GET DEAL
200 Used Today